381 related articles for article (PubMed ID: 26934656)
1. P300 acetyltransferase regulates fatty acid synthase expression, lipid metabolism and prostate cancer growth.
Gang X; Yang Y; Zhong J; Jiang K; Pan Y; Karnes RJ; Zhang J; Xu W; Wang G; Huang H
Oncotarget; 2016 Mar; 7(12):15135-49. PubMed ID: 26934656
[TBL] [Abstract][Full Text] [Related]
2. Speckle-type POZ protein suppresses lipid accumulation and prostate cancer growth by stabilizing fatty acid synthase.
Gang X; Xuan L; Zhao X; Lv Y; Li F; Wang Y; Wang G
Prostate; 2019 Jun; 79(8):864-871. PubMed ID: 30955223
[TBL] [Abstract][Full Text] [Related]
3. FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma.
Chianese U; Papulino C; Ali A; Ciardiello F; Cappabianca S; Altucci L; Carafa V; Benedetti R
J Transl Med; 2023 Jan; 21(1):32. PubMed ID: 36650542
[TBL] [Abstract][Full Text] [Related]
4. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers.
Uddin S; Siraj AK; Al-Rasheed M; Ahmed M; Bu R; Myers JN; Al-Nuaim A; Al-Sobhi S; Al-Dayel F; Bavi P; Hussain AR; Al-Kuraya KS
J Clin Endocrinol Metab; 2008 Oct; 93(10):4088-97. PubMed ID: 18682509
[TBL] [Abstract][Full Text] [Related]
5. p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis.
Zhong J; Ding L; Bohrer LR; Pan Y; Liu P; Zhang J; Sebo TJ; Karnes RJ; Tindall DJ; van Deursen J; Huang H
Cancer Res; 2014 Mar; 74(6):1870-1880. PubMed ID: 24480624
[TBL] [Abstract][Full Text] [Related]
6. ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3.
Zhou L; Song Z; Hu J; Liu L; Hou Y; Zhang X; Yang X; Chen K
Theranostics; 2021; 11(2):841-860. PubMed ID: 33391508
[TBL] [Abstract][Full Text] [Related]
7. Caveolin-1 interacts with a lipid raft-associated population of fatty acid synthase.
Di Vizio D; Adam RM; Kim J; Kim R; Sotgia F; Williams T; Demichelis F; Solomon KR; Loda M; Rubin MA; Lisanti MP; Freeman MR
Cell Cycle; 2008 Jul; 7(14):2257-67. PubMed ID: 18635971
[TBL] [Abstract][Full Text] [Related]
8. Caveolin-1 is required for the upregulation of fatty acid synthase (FASN), a tumor promoter, during prostate cancer progression.
Di Vizio D; Sotgia F; Williams TM; Hassan GS; Capozza F; Frank PG; Pestell RG; Loda M; Freeman MR; Lisanti MP
Cancer Biol Ther; 2007 Aug; 6(8):1263-8. PubMed ID: 17786030
[TBL] [Abstract][Full Text] [Related]
9. Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.
Tao T; Chen M; Jiang R; Guan H; Huang Y; Su H; Hu Q; Han X; Xiao J
Oncol Rep; 2017 Mar; 37(3):1430-1436. PubMed ID: 28184935
[TBL] [Abstract][Full Text] [Related]
10. HnRNP-L promotes prostate cancer progression by enhancing cell cycling and inhibiting apoptosis.
Zhou X; Li Q; He J; Zhong L; Shu F; Xing R; Lv D; Lei B; Wan B; Yang Y; Wu H; Mao X; Zou Y
Oncotarget; 2017 Mar; 8(12):19342-19353. PubMed ID: 28038443
[TBL] [Abstract][Full Text] [Related]
11. Exploring a role for fatty acid synthase in prostate cancer cell migration.
De Piano M; Manuelli V; Zadra G; Loda M; Muir G; Chandra A; Morris J; Van Hemelrijck M; Wells CM
Small GTPases; 2021 Jul; 12(4):265-272. PubMed ID: 33043786
[TBL] [Abstract][Full Text] [Related]
12. Cell suspension culture extract of Eriobotrya japonica attenuates growth and induces apoptosis in prostate cancer cells via targeting SREBP-1/FASN-driven metabolism and AR.
Hsieh PF; Jiang WP; Basavaraj P; Huang SY; Ruangsai P; Wu JB; Huang GJ; Huang WC
Phytomedicine; 2021 Dec; 93():153806. PubMed ID: 34740154
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk between osteoprotegerin (OPG), fatty acid synthase (FASN) and, cycloxygenase-2 (COX-2) in breast cancer: implications in carcinogenesis.
Goswami S; Sharma-Walia N
Oncotarget; 2016 Sep; 7(37):58953-58974. PubMed ID: 27270654
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes.
Damodaran S; Damaschke N; Gawdzik J; Yang B; Shi C; Allen GO; Huang W; Denu J; Jarrard D
BMC Cancer; 2017 Dec; 17(1):874. PubMed ID: 29262808
[TBL] [Abstract][Full Text] [Related]
15. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer.
Karantanos T; Karanika S; Wang J; Yang G; Dobashi M; Park S; Ren C; Li L; Basourakos SP; Hoang A; Efstathiou E; Wang X; Troncoso P; Titus M; Broom B; Kim J; Corn PG; Logothetis CJ; Thompson TC
Oncotarget; 2016 Jul; 7(29):46321-46334. PubMed ID: 27331874
[TBL] [Abstract][Full Text] [Related]
16. ACSL4 promotes prostate cancer growth, invasion and hormonal resistance.
Wu X; Deng F; Li Y; Daniels G; Du X; Ren Q; Wang J; Wang LH; Yang Y; Zhang V; Zhang D; Ye F; Melamed J; Monaco ME; Lee P
Oncotarget; 2015 Dec; 6(42):44849-63. PubMed ID: 26636648
[TBL] [Abstract][Full Text] [Related]
17. Genetic ablation of FASN attenuates the invasive potential of prostate cancer driven by Pten loss.
Bastos DC; Ribeiro CF; Ahearn T; Nascimento J; Pakula H; Clohessy J; Mucci L; Roberts T; Zanata SM; Zadra G; Loda M
J Pathol; 2021 Mar; 253(3):292-303. PubMed ID: 33166087
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of fatty acid synthase induced by EGFR/ERK activation promotes tumor growth in pancreatic cancer.
Bian Y; Yu Y; Wang S; Li L
Biochem Biophys Res Commun; 2015 Aug; 463(4):612-7. PubMed ID: 26043686
[TBL] [Abstract][Full Text] [Related]
19. PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.
Li Y; Su J; DingZhang X; Zhang J; Yoshimoto M; Liu S; Bijian K; Gupta A; Squire JA; Alaoui Jamali MA; Bismar TA
J Pathol; 2011 May; 224(1):90-100. PubMed ID: 21381033
[TBL] [Abstract][Full Text] [Related]
20. MDC1 functionally identified as an androgen receptor co-activator participates in suppression of prostate cancer.
Wang C; Sun H; Zou R; Zhou T; Wang S; Sun S; Tong C; Luo H; Li Y; Li Z; Wang E; Chen Y; Cao L; Li F; Zhao Y
Nucleic Acids Res; 2015 May; 43(10):4893-908. PubMed ID: 25934801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
